

ANNEXURE I

Format to be submitted by listed entity on quarterly basis

1. Name of Listed Entity **-Bafna Pharmaceuticals Limited**
 2. Quarter ending **- 30-Sep-2018**

I. Composition of Board of Directors										
Title (Mr./Ms)	Name of the Director	DI N	P A N	Category (Chairperson /Executive/ Non-Executive/ Independent/ Nominee)	Date of Appointment	Date of Cessation	Tenure	No of Directorship in listed entities including this listed entity	No of membership in Audit/ Stakeholder Committee(s) including this listed entity	No of post of Chairperson in Audit/ Stakeholder Committee held in listed entities including this listed entity
Mr.	BAFNA MAH AVEER CHAND	01458211	AACPB6411G	C & ED	01-Oct-2017	30-Sep-2020		1	2	0
Mr.	PARAS BAFNA	01933663	AASPB2717M	ED	01-Oct-2017	30-Sep-2020		1	1	0
Mr.	VRAJAMAN I	00052868	AAAPR3945H	ID	10-Sep-2014	09-Sep-2019	60	2	0	1
Mr.	SUNIL BAFNA	01458225	AHLPB3511D	ID	10-Sep-2014	09-Sep-2019	60	1	2	1
Mrs.	KSABITHA	02643259	APFPS3089F	ED	27-Mar-2015			1	0	0

II. Composition of Committees

Audit Committee			
Sr. No.	Name of the Director	Category	Chairperson/Membership
1	SUNIL BAFNA	ID	Member

2	V RAJAMANI	ID	Chairperson
3	BAFNA MAHAVEER CHAND	C & ED	Member

Stakeholders Relationship Committee

Sr. No.	Name of the Director	Category	Chairperson/Membership
1	SUNIL BAFNA	ID	Chairperson
2	PARAS BAFNA	ED	Member
3	BAFNA MAHAVEER CHAND	C & ED	Member

Risk Management Committee

Sr. No.	Name of the Director	Category	Chairperson/Membership
---------	----------------------	----------	------------------------

Nomination and Remuneration Committee

Sr. No.	Name of the Director	Category	Chairperson/Membership
1	SUNIL BAFNA	ID	Member
2	V RAJAMANI	ID	Member

III. Meeting of Board of Directors

Date(s) of Meeting (if any) in the previous quarter	Date(s) of Meeting (if any) in the relevant quarter	Maximum gap between any two
		76
28-May-2018	13-Aug-2018	

IV. Meeting of Committees

Name of the committee	Date(s) of meeting of the committee in the relevant quarter	Whether requirement of Quorum met (details)	Date(s) of meeting of the committee in the previous quarter	Maximum gap between any two consecutive (in number of days)
Audit Committee	13-Aug-2018	3	28-May-2018	76
Nomination & Remuneration Committee	13-Aug-2018	2	28-May-2018	

V. Related Party Transactions

Subject	Compliance status (Yes/No/NA)
Whether prior approval of audit committee obtained	Yes
Whether shareholder approval obtained for material RPT	Not Applicable

Whether details of RPT entered into pursuant to omnibus approval have been reviewed by Audit Committee	Yes
--	-----

VI. Affirmations

1. The composition of Board of Directors in terms of SEBI (Listing obligations and disclosure requirements) Regulations, 2015. - **No**
2. The composition of the following committees in terms of SEBI (Listing obligations and disclosure requirements) Regulations, 2015
 - a. Audit Committee - **Yes**
 - b. Nomination & remuneration committee - **No**
 - c. Stakeholders relationship committee - **Yes**
 - d. Risk management committee (applicable to the top 100 listed entities) - **Not applicable**
3. The committee members have been made aware of their powers, role and responsibilities as specified in SEBI (Listing obligations and disclosure requirements) Regulations, 2015. - **Yes**
4. The meetings of the board of directors and the above committees have been conducted in the manner as specified in SEBI (Listing obligations and disclosure requirements) Regulations, 2015. - **Yes**
5. a. This report and/or the reports submitted in the previous quarter has been placed before Board of Directors. - **Yes**
 b. Any comments/observations/advice of Board of Directors may be mentioned here:

Bafna Pharmaceuticals Limited is under Corporate Insolvency Resolution Process (CIRP) under I&B Code 2016? passed by the National Company Law Tribunal, Chennai vide its Order dated 16th July 2018. The Composition of the Board of Directors and Nomination and Remuneration Committee? is not in terms of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Name : **JITENDRA KUMAR PAL**
 Designation : **Company Secretary**

ANNEXURE III

Affirmations

Broad Heading	Regulation Number	Compliance Status
Copy of the annual report including balance sheet, profit and loss account, directors report, corporate governance report, business responsibility report displayed on website	46(2)	Yes
Presence of Chairperson of Audit Committee at the Annual General Meeting	18(1)(d)	Yes
Presence of Chairperson of the nomination and remuneration committee at the annual general meeting	19(3)	Yes
Whether "Corporate Governance Report" disclosed in Annual Report	34(3) read with para C of Schedule V	Yes

Note:

1. In the column "Compliance Status", compliance or non-compliance may be indicated by Yes/No/N.A. For example, if the Board has been composed in accordance with the requirements of Listing Regulations, "Yes" may be indicated. Similarly, in case the Listed Entity has no related party transactions, the words "N.A." may be indicated.
2. If status is "No" details of non-compliance may be given here.
3. If the Listed Entity would like to provide any other information the same may be indicated here. **Bafna Pharmaceuticals Limited is under Corporate Insolvency Resolution Process (CIRP) under I&B Code 2016?passed by the National Company Law Tribunal, Chennai vide its Order dated 16th July 2018. The Composition of the Board of Directors and Nomination and Remuneration Committee?is not in terms of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015**

Name : **JITENDRA KUMAR PAL**
Designation : **Company Secretary**